Search results
Results from the WOW.Com Content Network
The Regeneron Science Talent Search, known for its first 57 years [1] as the Westinghouse Science Talent Search, and then as the Intel Science Talent Search (Intel STS) from 1998 through 2016, [2] is a research-based science competition in the United States for high school seniors.
Amber Zoe Yang (born 1999) was a finalist in the 2017 Regeneron STS, and was awarded 2nd place at the 2016 ISEF for her space science project. She attends the Trinity Preparatory School, Winter Park, Florida. JPL · 33337: 33343 Madorobin: 1998 XT 10: Mado Robin (1918–1960) was a French coloratura soprano, noted for her extreme vocal range ...
In 2017 Regeneron Science Talent Search, Harker had nine semi-finalists, tied as most of any school in USA with two other schools and had three finalists most of any school alone in USA. [42] [43] In 2018 Regeneron STS, Harker had six semi-finalists, tied as most of any school in California and two finalists.
Regeneron and partner Sanofi's application for the label expansion of Dupixent has been accepted by the regulatory body in Europe. The application is also under review in the United States.
Mammoth's CRISPR-based gene editing platform and Regeneron's delivery technologies will be used to create disease-modifying medicines that can be delivered to tissues beyond the liver. CRISPR ...
In 2019, she was one of 40 finalists for the Regeneron Science Talent Search (STS) for her invention of a sensor that could detect arsenic in drinking water from underground sources and received a $25,000 prize. [4] Chadha was featured on an episode of Mission Unstoppable that aired on June 12, 2021. [5]
Regeneron was seeking regulatory approval of its therapy, linvoseltamab, in patients with multiple myeloma whose cancer has returned or worsened after at least three prior lines of treatment. The ...
TARRYTOWN, N.Y., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the Biologics License Application (BLA) for linvoseltamab in relapsed/refractory (R/R) multiple myeloma (MM) that has progressed after at least three prior therapies.